RBC Asks 'What's the Holdup?' on Lam Research's (LRCX) Deal with KLA-Tencor (KLAC)

Cowen Bullish on Lam Research/KLA-Tencor Deal Amid Delay; Affirms Lam Research at 'Outperform' (LRCX)

Cowen and Company affirms Lam Research (Nasdaq: LRCX) at Outperform with a price target of $95 following news of a delay in closing its deal with KLA-Tencor.

Analyst Tim Arcuri commented today: Time kills M&A deals and most consummated deals don't extend much beyond 12mos. Having said that, we continue to see the holdup here related to procedural remedies and KLAC's status as a "process neutral"... More

Needham & Company Sees Lam Research (LRCX), KLA-Tencor (KLAC) Closing Deal in H117 Amid Regulatory Risks

Needham & Company affirms Lam Research (Nasdaq: LRCX) with a Buy rating and $105 price target amid news of a delay to its merger with KLA-Tencor this morning.

Analyst Y. Edwin Mok commented today, Before market open, LRCX and KLAC issued a press release effectively pushing out the timeline of achieving regulatory clearance for its acquisition of KLAC [Hold]. This is the third time the target date has been delayed, extending the regulatory... More

Lam Research (LRCX), KLA-Tencor (KLAC) Update on Merger; Sees Extension to Obtain Regulatory Clearances

Lam Research Corporation and KLA-Tencor Corporation provided an update on their planned business combination. As previously disclosed, the parties continue to discuss their proposed merger, including potential remedies, with the staff of the Department of Justice (the "DOJ"), and with competition authorities in Korea, Japan and China. The companies... More